The first treatment for low-grade upper tract urothelial cancer (UTUC) has received FDA approval.

Although US health officials were focused on combating coronavirus disease 2019 when mitomycin gel was approved in mid-April, the director of the FDA’s Oncology Center of Excellence said that “patients with cancer and their unique needs continue to be a top priority” for the agency.